Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Neoplasms 5Stomach Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Advanced Solid Tumors 4Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Advanced Solid Tumor 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thoracic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Lung Cancer 1

Interventions

tremelimumab 1durvalumab 1Injections 1Docetaxel 1Bevacizumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Platinum-resistant Recurrent Ovarian Cancer × Injections × Clear all
NCT05325229 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
94 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡